Skip to main
PROF
PROF logo

PROF Stock Forecast & Price Target

PROF Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Profound Medical Corp is strategically positioning itself for growth, anticipating an increase in its US installed base of TULSA-PRO systems from approximately 53 to 75 by the end of 2024, bolstered by a mixed revenue model comprising capital placements and recurring revenue. The upcoming changes to TULSA reimbursement, including the introduction of an ASC code in early 2024 and CPT codes in early 2025, are expected to significantly enhance access to prostate cancer treatments, potentially increasing the installed base substantially. Additionally, advancements in the TULSA-PRO system, notably through recent software enhancements like the “Thermal Boost Pro,” underscore the growing physician comfort with the technology, which reflects positively on the company's long-term utilization growth potential.

Bears say

Profound Medical Corp's reliance on the success of its TULSA-PRO system and associated CAPTAIN study significantly heightens the company's risk profile, as failure in these areas could lead to diminished adoption rates and worsening reimbursement prospects. The company's single-technology focus further exacerbates this risk, as an ineffective sales strategy could result in stalled or declining revenue growth. Additionally, adverse clinical data or negative recommendations from medical societies could severely impact the product's market acceptance and overall commercial potential amidst a challenging funding and valuation environment in the MedTech sector.

PROF has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Profound Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Profound Medical Corp (PROF) Forecast

Analysts have given PROF a Buy based on their latest research and market trends.

According to 7 analysts, PROF has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Profound Medical Corp (PROF)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.